364 results on '"Josephs, Debra"'
Search Results
2. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
3. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
4. Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave
5. Update on the prognostic value of a novel immune-related toxicity grading system (OST score) in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICI).
6. Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.
7. Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19
8. Protective effects of allergic diseases in COVID‐19 outcomes: A retrospective cohort study in UK Biobank in the general population and in patients with cancer
9. A cohort profile of the Graham Roberts study cohort
10. Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer
11. Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study
12. Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort
13. Anita’s Vision
14. Cohort profile: King’s Health Partners bladder cancer biobank
15. Supplementary figures from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
16. Supplementary Table S1 from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
17. Data from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
18. Supplementary Materials and Methods from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
19. Supplementary Figure Legends from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
20. Supplementary Figure S1 from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
21. Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic
22. Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review
23. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study
24. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study
25. Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study
26. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
27. Beta-glucan contamination of pharmaceutical products: How much should we accept?
28. 011 A case of a neurological immune-related adverse event associated with ipilimumab/nivolumab
29. [99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression.
30. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
31. Additional file 1 of Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19
32. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper
33. Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data
34. Clinical and Translational Significance of Basophils in Patients with Cancer
35. Safe Provision of Systemic Anti-Cancer Treatment for Urological Cancer Patients During COVID-19: A Tertiary Centre Experience in the First Wave of COVID-19
36. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre
37. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
38. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
39. Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment
40. My epilepsy story – The Anita Kaufmann Foundation
41. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments
42. Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial
43. Additional file 1 of Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study
44. IgG4 subclass antibodies impair antitumor immunity in melanoma
45. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
46. The impact of COVID-19 on delivery of systemic anti-cancer treatment in urological cancer patients: A comparison with 2019 data from Guy’s Cancer Center.
47. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
48. Checking the chart in severe gastritis: a case in point
49. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application
50. Molecular imaging in clinical trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.